220 related articles for article (PubMed ID: 2151441)
1. Comparison of the target sites and mechanisms of action of glycopeptide and lipoglycodepsipeptide antibiotics.
Reynolds PE; Somner EA
Drugs Exp Clin Res; 1990; 16(8):385-9. PubMed ID: 2151441
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of peptidoglycan biosynthesis by ramoplanin.
Somner EA; Reynolds PE
Antimicrob Agents Chemother; 1990 Mar; 34(3):413-9. PubMed ID: 2334153
[TBL] [Abstract][Full Text] [Related]
3. Complexation of peptidoglycan intermediates by the lipoglycodepsipeptide antibiotic ramoplanin: minimal structural requirements for intermolecular complexation and fibril formation.
Cudic P; Kranz JK; Behenna DC; Kruger RG; Tadesse H; Wand AJ; Veklich YI; Weisel JW; McCafferty DG
Proc Natl Acad Sci U S A; 2002 May; 99(11):7384-9. PubMed ID: 12032292
[TBL] [Abstract][Full Text] [Related]
4. Structure, biochemistry and mechanism of action of glycopeptide antibiotics.
Reynolds PE
Eur J Clin Microbiol Infect Dis; 1989 Nov; 8(11):943-50. PubMed ID: 2532132
[TBL] [Abstract][Full Text] [Related]
5. Extraction and Analysis of Peptidoglycan Cell Wall Precursors.
Binda E; Carrano L; Marcone GL; Marinelli F
Methods Mol Biol; 2016; 1440():153-70. PubMed ID: 27311671
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms and implications of glycopeptide resistance in enterococci.
Derlot E; Courvalin P
Am J Med; 1991 Sep; 91(3B):82S-85S. PubMed ID: 1656750
[TBL] [Abstract][Full Text] [Related]
7. The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation.
Brötz H; Bierbaum G; Reynolds PE; Sahl HG
Eur J Biochem; 1997 May; 246(1):193-9. PubMed ID: 9210483
[TBL] [Abstract][Full Text] [Related]
8. The mechanism of action of ramoplanin and enduracidin.
Fang X; Tiyanont K; Zhang Y; Wanner J; Boger D; Walker S
Mol Biosyst; 2006 Jan; 2(1):69-76. PubMed ID: 16880924
[TBL] [Abstract][Full Text] [Related]
9. Presence of UDP-N-acetylmuramyl-hexapeptides and -heptapeptides in enterococci and staphylococci after treatment with ramoplanin, tunicamycin, or vancomycin.
Billot-Klein D; Shlaes D; Bryant D; Bell D; Legrand R; Gutmann L; van Heijenoort J
J Bacteriol; 1997 Aug; 179(15):4684-8. PubMed ID: 9244253
[TBL] [Abstract][Full Text] [Related]
10. Functional analysis of the lipoglycodepsipeptide antibiotic ramoplanin.
Cudic P; Behenna DC; Kranz JK; Kruger RG; Wand AJ; Veklich YI; Weisel JW; McCafferty DG
Chem Biol; 2002 Aug; 9(8):897-906. PubMed ID: 12204689
[TBL] [Abstract][Full Text] [Related]
11. Chemistry and biology of the ramoplanin family of peptide antibiotics.
McCafferty DG; Cudic P; Frankel BA; Barkallah S; Kruger RG; Li W
Biopolymers; 2002; 66(4):261-84. PubMed ID: 12491539
[TBL] [Abstract][Full Text] [Related]
12. On the mechanism of action of vancomycin: inhibition of peptidoglycan synthesis in Gaffkya homari.
Hammes WP; Neuhaus FC
Antimicrob Agents Chemother; 1974 Dec; 6(6):722-8. PubMed ID: 4451345
[TBL] [Abstract][Full Text] [Related]
13. New insights into glycopeptide antibiotic binding to cell wall precursors using SPR and NMR spectroscopy.
Treviño J; Bayón C; Ardá A; Marinelli F; Gandolfi R; Molinari F; Jimenez-Barbero J; Hernáiz MJ
Chemistry; 2014 Jun; 20(24):7363-72. PubMed ID: 24805824
[TBL] [Abstract][Full Text] [Related]
14. Molecular modeling of Gram-positive bacteria peptidoglycan layer, selected glycopeptide antibiotics and vancomycin derivatives modified with sugar moieties.
Ślusarz R; Szulc M; Madaj J
Carbohydr Res; 2014 May; 389():154-64. PubMed ID: 24685455
[TBL] [Abstract][Full Text] [Related]
15. Rethinking ramoplanin: the role of substrate binding in inhibition of peptidoglycan biosynthesis.
Helm JS; Chen L; Walker S
J Am Chem Soc; 2002 Nov; 124(47):13970-1. PubMed ID: 12440876
[TBL] [Abstract][Full Text] [Related]
16. Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
Printsevskaya SS; Pavlov AY; Olsufyeva EN; Mirchink EP; Preobrazhenskaya MN
J Med Chem; 2003 Mar; 46(7):1204-9. PubMed ID: 12646030
[TBL] [Abstract][Full Text] [Related]
17. In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile.
Biavasco F; Manso E; Varaldo PE
Antimicrob Agents Chemother; 1991 Jan; 35(1):195-7. PubMed ID: 1826593
[TBL] [Abstract][Full Text] [Related]
18. Modification of peptidoglycan precursors is a common feature of the low-level vancomycin-resistant VANB-type Enterococcus D366 and of the naturally glycopeptide-resistant species Lactobacillus casei, Pediococcus pentosaceus, Leuconostoc mesenteroides, and Enterococcus gallinarum.
Billot-Klein D; Gutmann L; Sablé S; Guittet E; van Heijenoort J
J Bacteriol; 1994 Apr; 176(8):2398-405. PubMed ID: 8157610
[TBL] [Abstract][Full Text] [Related]
19. Resistance to glycopeptide antibiotics in the teicoplanin producer is mediated by van gene homologue expression directing the synthesis of a modified cell wall peptidoglycan.
Beltrametti F; Consolandi A; Carrano L; Bagatin F; Rossi R; Leoni L; Zennaro E; Selva E; Marinelli F
Antimicrob Agents Chemother; 2007 Apr; 51(4):1135-41. PubMed ID: 17220405
[TBL] [Abstract][Full Text] [Related]
20. Glycopeptide antibiotics and their novel semi-synthetic derivatives.
Jeya M; Moon HJ; Lee KM; Kim IW; Lee JK
Curr Pharm Biotechnol; 2011 Aug; 12(8):1194-204. PubMed ID: 21470154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
